It is not $300m, it is 'Mithra will receive down payment and milestone fees in equity & cash of at least USD 295 million', the key word here is 'milestone' and 'equity and cash'.
Mithra's worst case scenario is ~4.5b Euros in revenue during the 20 year contract. For a single product which perfectly compliments MYX's women's health division. It would also be 'the first native estrogen approved in a contraceptive product in the US', and first new estrogen in 50 years. It sounds like it is going to attract a lot of positive attention for those two points alone.
I think MYX is oversold as it is, and this sets up a potential multi-year, multi-bagger.
MYX Price at posting:
53.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)